Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024GlobeNewsWire • 04/09/24
Shattuck Labs Announces Participation in Upcoming 23rd Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/01/24
Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D.GlobeNewsWire • 03/04/24
Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business HighlightsGlobeNewsWire • 02/29/24
Ono Enters into a Drug Discovery Collaboration and Option Agreement with Shattuck Labs to Generate Bifunctional Fusion ProteinsPRNewsWire • 02/14/24
Shattuck Labs Enters into Strategic Collaboration and License Agreement with Ono Pharmaceutical to Generate Bifunctional Fusion Proteins for the Treatment of Autoimmune and Inflammatory DiseasesGlobeNewsWire • 02/13/24
Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2024GlobeNewsWire • 01/08/24
Shattuck Labs Announces Presentation at Upcoming 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/04/24
Shattuck Labs Announces $50 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded WarrantsGlobeNewsWire • 12/21/23
Shattuck Labs Announces Positive Initial Topline Data from Ongoing Phase 1 A/B Dose Expansion Clinical Trial of SL-172154 with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) PatientsGlobeNewsWire • 12/13/23
Shattuck Labs to Host Investor Call and Webcast to Share Initial Clinical Trial Data from Phase 1A/B Dose-Expansion Cohorts in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53m Acute Myeloid Leukemia (AML) and Review of Dose-Escalation Data from the American Society of Hematology (ASH) 2023 Annual Meeting on December 13, 2023GlobeNewsWire • 12/05/23
Shattuck Labs Announces Participation in Upcoming 6th Annual Evercore ISI HealthCONx ConferenceGlobeNewsWire • 11/14/23
Shattuck Labs Reports Third Quarter 2023 Financial Results and Recent Business HighlightsGlobeNewsWire • 11/09/23
Shattuck Labs to Report Third-Quarter 2023 Financial Results on November 9, 2023GlobeNewsWire • 11/06/23
Shattuck Labs to Present Topline Data from Phase 1 A/B Clinical Trial of SL-172154 in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS) Patients at the American Society of Hematology (ASH) 2023 Annual MeetingGlobeNewsWire • 11/02/23
Shattuck Labs, Inc. (STTK) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/10/23
Shattuck Labs Reports Second Quarter 2023 Financial Results and Recent Business HighlightsGlobeNewsWire • 08/10/23
Shattuck Labs to Present Complete Dose-Escalation Data from Phase 1A Monotherapy Clinical Trial of SL-172154 in Platinum-Resistant Ovarian Cancer (PROC) at the American Society of Clinical Oncology (ASCO) 2023 Annual MeetingGlobeNewsWire • 05/25/23
Shattuck Labs, Inc. (STTK) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research • 05/09/23
Shattuck Labs Reports First Quarter 2023 Financial Results and Recent Business HighlightsGlobeNewsWire • 05/09/23